Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00963924 · ClinicalTrials.gov registry record · NA
D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 54
- Enrollment target
NCT00963924: Completed NA study, sponsored by Massachusetts General Hospital.
NCT00963924 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 54 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00963924, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 54 participants
- Enrollment target
Study Summary
This study seeks to examine the effects of D-cycloserine augmentation on cognitive remediation for patients diagnosed with schizophrenia. We will test the hypotheses that D-cycloserine will significantly improve cognitive performance, negative symptoms, and measures of functioning compared to placebo when combined with eight weeks of cognitive remediation. We expect that these effects will persist when assessed at six-month follow up.
Interventions
- DRUG Placebo
- BEHAVIORAL Cognitive Remediation
- DRUG D-cycloserine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2009-08 |
| Est. Completion | 2011-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00963924
The ClinicalTrials.gov registry entry for NCT00963924 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00963924 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00963924 about?
NCT00963924 is a clinical study titled "D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia". This study seeks to examine the effects of D-cycloserine augmentation on cognitive remediation for patients diagnosed with schizophrenia. We will test the hypotheses that D-cycloserine will significantly improve cognitive performance, negative symptoms, and measures of functioning compared to placeb...
What is the current status of trial NCT00963924?
This trial is currently completed. It is a NA study. The enrollment target is 54 participants. The study started on 2009-08. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00963924?
The interventions under investigation include: Placebo (DRUG), Cognitive Remediation (BEHAVIORAL), D-cycloserine (DRUG).
Who is sponsoring clinical trial NCT00963924?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.